Full Name
Krista McKerracher
Job Title
Managing Director
Company
Fig Advisory LLC
Speaker Bio
Krista McKerracher is a retired biopharmaceutical leader with 35+ years of experience spanning Canadian, U.S. & global commercial and development roles. She is known for bringing a strong commercial orientation to the drug development process.
In her last corporate role, McKerracher was VP, Head of Hemoglobinopathy Programs at CRISPR Therapeutics (NASDAQ: CRSP) where she took the first CRISPR-edited autologous cellular program through IND and into the clinic. Previously, McKerracher was Vice President & Global Program Franchise Head at Novartis Oncology, where she directed a large cross-functional team of drug development professionals. Prior to Novartis, McKerracher held a series of roles over 14 years at the Johnson & Johnson family of companies in Canada and the US.
In 2017, McKerracher founded FIG Advisory LLC, a consultancy serving early-stage companies on development and fund-raising strategy. She serves on the Board of Nervgen Pharma (TSXV: NGEN, OTCQX: NGENF; Chair, Nomination & Governance Committee; member, Compensation and Science Committees). She serves on Advisory Boards to Hemex Health, Cureleads, and BioAxone Biosciences, and is a mentor at Springboard, an incubator for female-led healthcare and technology companies. She previously served on the Alumni Council and the Capital Campaign Committee at the University of Waterloo.
McKerracher holds a BSc (Hon) in Applied Health Studies from the University of Waterloo and an MBA from York University. She is an avid skier, golfer, and boater who loves to cook and learn all she can about wine.
Key boards: Nervgen Pharma (TSXV: NGEN, OTCQX: NGENF) (Nomination & Governance Committee Chair; Compensation and Science Committees), Hemex Health Advisory Board, Cureleads Advisory Board, BioAxone Biosciences Advisory Board
In her last corporate role, McKerracher was VP, Head of Hemoglobinopathy Programs at CRISPR Therapeutics (NASDAQ: CRSP) where she took the first CRISPR-edited autologous cellular program through IND and into the clinic. Previously, McKerracher was Vice President & Global Program Franchise Head at Novartis Oncology, where she directed a large cross-functional team of drug development professionals. Prior to Novartis, McKerracher held a series of roles over 14 years at the Johnson & Johnson family of companies in Canada and the US.
In 2017, McKerracher founded FIG Advisory LLC, a consultancy serving early-stage companies on development and fund-raising strategy. She serves on the Board of Nervgen Pharma (TSXV: NGEN, OTCQX: NGENF; Chair, Nomination & Governance Committee; member, Compensation and Science Committees). She serves on Advisory Boards to Hemex Health, Cureleads, and BioAxone Biosciences, and is a mentor at Springboard, an incubator for female-led healthcare and technology companies. She previously served on the Alumni Council and the Capital Campaign Committee at the University of Waterloo.
McKerracher holds a BSc (Hon) in Applied Health Studies from the University of Waterloo and an MBA from York University. She is an avid skier, golfer, and boater who loves to cook and learn all she can about wine.
Key boards: Nervgen Pharma (TSXV: NGEN, OTCQX: NGENF) (Nomination & Governance Committee Chair; Compensation and Science Committees), Hemex Health Advisory Board, Cureleads Advisory Board, BioAxone Biosciences Advisory Board
Speaking At
